Background
Phase III, double-blind, placebo-controlled RCT. 726 postmenopausal women with HR+ HER2- advanced breast cancer in first- or second-line setting (prior AI allowed). Fulvestrant backbone selected to capture patients with AI-pretreated or hormone-naive disease.
Interventions and follow up
Arm A: Ribociclib 600mg days 1–21 of 28-day cycle + fulvestrant 500mg IM q28d (loading dose on d1 and d15 of cycle 1)
Arm B: Placebo + fulvestrant 500mg IM q28d
Primary endpoint: Progression-free survival (PFS)
mFollow up: 56.3 months (OS analysis)
Arm B: Placebo + fulvestrant 500mg IM q28d
Primary endpoint: Progression-free survival (PFS)
mFollow up: 56.3 months (OS analysis)
Results
PFS: 20.5 vs 12.8mo, HR 0.593, 95% CI 0.480–0.732, P<.001
OS (final): 53.7 vs 41.5mo, HR 0.73, 95% CI 0.589–0.900, P=.004
OS (final): 53.7 vs 41.5mo, HR 0.73, 95% CI 0.589–0.900, P=.004
Adverse events
Hematologic (grade ≥3): Neutropenia 53.3% vs 0.3%
Cardiac: QTc prolongation grade ≥3 2.4%
Hepatic: Hepatotoxicity grade ≥3 4.1%
Dose modification: Dose reductions 37.9%; discontinuation 6.9%
Cardiac: QTc prolongation grade ≥3 2.4%
Hepatic: Hepatotoxicity grade ≥3 4.1%
Dose modification: Dose reductions 37.9%; discontinuation 6.9%
Conclusions
Ribociclib + fulvestrant significantly improved OS vs placebo + fulvestrant in postmenopausal HR+ HER2- advanced BC across first and second line, with a 12-month OS gain. Demonstrated the CDK4/6 inhibitor OS benefit extends to the fulvestrant backbone and second-line setting.
Key Limitations
Mixed first- and second-line population complicates interpretation; subgroup analysis showed benefit in both lines but trial was not individually powered for each. QTc monitoring requirement is a practical limitation. Fulvestrant dosing (500mg) requires IM injection — adherence and access may vary in clinical practice. The OS benefit in second-line may be partly attributable to patient selection (prior AI use reflects more indolent disease).
Clinical Context
MONALEESA-3 established ribociclib + fulvestrant as a standard option in first- and second-line postmenopausal HR+ HER2- mBC, with FDA approval. Combined with MONALEESA-2 and MONALEESA-7, ribociclib has demonstrated OS benefit in all three CDK4/6 inhibitor trials — the only CDK4/6 inhibitor to show this across menopausal status and backbone. ESMO-MCBS score: 5.